XCancer
Telix Pharmaceuticals

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Description:

This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).

Sponsor:

Telix Pharmaceuticals

Government Study Link:

NCT07238322 - Click here to see study on

ClinicalTrials.gov

FET

Isotope(s):
Target(s):
  • Amino Acid Transport
Ligand Class: Small Molecules
Inclusion
  • Underwent \[18F\]FET PET imaging as part of routine clinical care after completion of primary treatment (surgery, radiation therapy, and/or chemotherapy).
  • Evidence of radiographic suspicion of recurrence or progression on MRI at the time of \[18F\]FET PET imaging.
Exclusion
  • Any institutional or regulatory requirement that precludes data sharing or inclusion in retrospective research studies.
  • Did not undergo \[18F\]FET PET imaging as part of routine clinical care.

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...